Recombinant Human BMP-2
Induced alkaline phosphatase in ATDC5 cells assay for Human BMP-2. Alkaline phosphatase was measured to calculate the ED50, which is as expected less than 250 ng/ml.
Non-reducing (-) and reducing (+) conditions in a 4 - 20% Tris-Glycine gel stained with Coomassie Blue. 1 μg of protein was loaded in each lane. Human BMP-2 has a predicted Mw of 26.0 kDa (each monomer is 13.0 kDa).
Achieve Purchasing Synergy
Request a quote at [email protected] for 2 or more vials of any Growth Factor to receive a discount. Discounts range from 5 to 20% according to the size of your order.
PODS® Growth Factors
The product is currently not available as PODS®, please check back in the future.Description
Bone Morphogenic Protein 2 (BMP-2) is a member of the Bone Morphogenetic Protein (BMP) family. These proteins are synthesized as large precursor molecules which are cleaved by proteolytic enzymes. BMP-2 functions as a potent inducer of bone and cartilage development. Active BMP-2 consists of forming a homodimer or a heterodimer with a related BMP, such as BMP-7. BMP-2 signals through type I and type II receptor tyrosine kinases in conjuction with SMAD proteins to directly promote osteoblast differentiation. BMP-2 is also important during cardiac development and supports epicardial cell migration.Activity Assay
Human BMP-2 is fully biologically active when compared to standard. The activity is determined by the alkaline phosphatase activity induced in ATDC5 cells and it is typically less than 250 ng/ml. This corresponds to an expected specific activity of 4.0 x 103 units/mg.AA Sequence
MQAKHKQRKR LKSSCKRHPL YVDFSDVGWN DWIVAPPGYH AFYCHGECPF PLADHLNSTN HAIVQTLVNS VNSKIPKACC VPTELSAISM LYLDENEKVV LKNYQDMVVE GCGCRAlternative Names
Bone morphogenetic protein 2, bone morphogenetic protein 2A, BMP-2A, BMP2, BMP2A| Product Details | |
|---|---|
| Length | 115 / 230 aa |
| Molecular Weight | 13.0 / 26.0 kDa |
| Structure | Dimer |
| Source | E. coli |
| Accession Number | P12643 |
| Purity | ≥95% determined by reducing and non-reducing SDS-PAGE |
| Endotoxin Level | ≤1.00 EU/μg as measured by kinetic LAL |
| Formulation | Lyophilized from a sterile (0.2 micron) filtered aqueous solution containing 0.1% Trifluoroacetic Acid (TFA) |
| Reconstitution | Centrifuge vial before opening. When reconstituting the product, gently pipet and wash down the sides of the vial to ensure full recovery of the protein into solution. It is recommended to reconstitute the lyophilized product with sterile water at 0.1 mg/ml, which can be further diluted into other aqueous solutions. |
| Stability and Storage |
12 months from date of receipt when stored at -20°C to -80°C as supplied. 1 month when stored at 4°C after reconstituting as directed. 3 months when stored at -20°C to -80°C after reconstituting as directed. |
Citations
Bao W, Gao M, Cheng Y, Lee HJ, Zhang Q, Hemingway S, Luo Z, Krol A, Yang G, An J. Biomodification of PCL Scaffolds with Matrigel, HA, and SR1 Enhances De Novo Ectopic Bone Marrow Formation Induced by rhBMP-2. (2015).
Documents
GFH53 Datasheet.pdfMSDS Recombinant Proteins.pdf
